Pfizer

Pfizer Shares Waver After Seagen’s Mixed Top‑Line Data on Origin Cancer Therapy

Pfizer Shares Slip After Seagen’s Origin Cancer Drug Delivers Mixed Top‑line Results

Pfizer’s Lung Cancer Hope Falters in Late‑Stage Trial

Pfizer’s Lung‑Cancer Experiment Stumbles: No Survival Edge Found

The Weight Loss Drug Revolution: Navigating a Fast-Evolving Market

Day 2 at ASCO 2026: Fresh Data from BioNTech‑Pfizer, Kelun, Merck and Insights from Dr. Pazdur

A Digital Pioneer Departs: Andrew Baum's Exit from Pfizer

Navigating Midweek Markets: Key Stocks Stealing the Spotlight

Unpacking the Market's Best Bets: Four 'Final Trades' Worth Your Attention

The Shifting Sands of Pharma: FDA's Grip, Global Ambitions, and the Future of Medicine

Pfizer's Bold Gambit: A Nearly Half-Billion Dollar Bet on China's Obesity Market

Unpacking India's Market Movers: A Day of Peaks, Pits, and Pivotal News

Pharmalot's Pulse Check: Navigating Pharma's Twists and Turns

Navigating the Market: Expert Takes on Delta, Amex, Pfizer, and Harmony Gold

Beyond the Annual Jab: Unpacking mRNA's Potential to Transform Flu Vaccines

The Double-Edged Shot: Pfizer's mRNA Flu Vaccine Looks Great, But Here's the Hiccup

The Siren Song of Scale: Why Big Pharma's Mega-Mergers So Often Fall Flat

The Great Weight Race: Can New Contenders Navigate the Treacherous Path of Next-Gen Obesity Drugs?

The Billion-Dollar Battle for a Breakthrough: Pfizer's Big Bet on Oral Obesity Drugs

The Race for a Breakthrough: Pfizer's Bold Bet on Battling Obesity, Outmaneuvering Novo Nordisk

The Great Pharmaceutical Scramble: Pfizer Bags Metsea in High-Stakes Obesity Drug Duel

The Billion-Dollar Battle for the Future of Weight Loss: Pfizer Jumps into the Ring

The Weight of Ambition: Pfizer’s Bold Move into the Obesity Race

The Battle for the Next Blockbuster: Pfizer Steps Up in the Obesity Drug Wars

The Pharmaceutical Thunderdome: Pfizer's Bold Play in the Billion-Dollar Battle for Obesity Drugs

The Great Weight-Loss Gambit: Pfizer Jumps into the Billion-Dollar Battle for Obesity Treatment Supremacy

The Great GLP-1 Gold Rush: Pfizer Jumps into the Billion-Dollar Battle for Weight Loss Dominance

The Great Weight-Loss Race: Pfizer's Billion-Dollar Gambit to Conquer Obesity

The High-Stakes Game of Weight Loss: Pfizer's Gambit in the GLP-1 Gold Rush

The Pharma Gambit: Why Pfizer Might Just Snatch Metsara from Novo's Grasp

The Billion-Dollar Beatdown: How Novo Nordisk Clinched Metsera in a High-Stakes Pharma Showdown

The Earnings Game: Big Tech's Bumpy Ride and the Surprises That Moved Markets

The Billion-Dollar Standoff: Pfizer Takes On Novo Nordisk for a Slice of the Future

The Weight-Loss Gold Rush: Why All Eyes Are On Viking Therapeutics After a Hefty Biotech Deal

The Billion-Dollar Standoff: Pfizer Unleashes on Novo Nordisk in Metsera Bid Battle

The Great Weigh-In: Pharma's Fierce Battle for the Future of Obesity, and What Else Keeps Them Up at Night

Alberta's Vaccination Drive Accelerates: Second Phase of COVID-19 Bookings Now Open

A New Dawn for Bladder Cancer Patients: Astellas & Pfizer's Combination Therapy Halves Mortality Risk

Rethinking Drug Costs: Trump's Bold Bid to Reshape Pharmaceutical Pricing